Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC

• Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patients • Expansion based on safety and strong initial efficacy results • Data updates expected throughout CY2023 and cost-efficient approach through investigator-initiated trial will further inform options related to 1L NSCLC development • Clinical data to date shows efti u